Dennis Cooper, MD
Medical Oncology · Bronx, NYNPI 1154319093
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Seagen Inc. accounts for 63.0% of it on its own, with 13 other manufacturers making up the rest.
Across 113 payments — averaging $680.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$48K
- Gilead$20K
- Pfizer$4K
- E.r. Squibb & Sons, L.L.C.$3K
- Janssen Research & Development, LLC$1K
- Karyopharm Therapeutics Inc.$148
- plus $425 from 8 others
Across 184 payments — averaging $8977.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$993K
- Janssen Research & Development, LLC$485K
- Novartis$131K
- Bristol Myers Squibb$42K
What the payments were for
- Consulting fees$19,83826%
- Speaking & faculty fees$42,91556%
- Travel & lodging$10,36613%
- Food & beverage$3,7285%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 42 | $48,460 |
| Gilead | 32 | $19,501 |
| Pfizer | 9 | $4,476 |
| E.r. Squibb & Sons, L.L.C. | 1 | $2,768 |
| Janssen Research & Development, LLC | 12 | $1,129 |
| Karyopharm Therapeutics Inc. | 1 | $148 |
| AbbVie | 5 | $120 |
| Bristol Myers Squibb | 3 | $108 |
| Acrotech Biopharma Inc. | 2 | $60 |
| GSK | 2 | $47 |
| Mallinckrodt Hospital Products Inc. | 1 | $33 |
| Sanofi-aventis U.S. LLC | 1 | $26 |
| Johnson & Johnson | 1 | $20 |
| Rigel Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$76,906 in reported general payments places this provider in the 80th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValacyclovirValacyclovir Hcl | 31 | $1,051 |
| Potassium Chloride | 12 | $50 |
| Amlodipine Besylate | 17 | $7 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Bronx
- Joseph SparanoBronx$125K
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Maria TheodoulouAlbany$1.1M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
- Anthony MatoIthaca$909K
- Ehsan MalekBuffalo$826K
- Ghassan Abou-AlfaNew York$825K
- Miguel PeralesNew York$769K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.